CG
BLCM

Cutler Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Cutler Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-120
Closed -$3K – 5471
2017
Q4 		$3K Sell
120
-2,020
-94% -$198K ﹤0.01% 4030
2017
Q3 		$38K Buy
2,140
+210
+11% +$22.1K ﹤0.01% 2507
2017
Q2 		$46K Buy
1,930
+470
+32% +$58.3K ﹤0.01% 2583
2017
Q1 		$6K Buy
1,460
+250
+21% +$32.7K ﹤0.01% 4624
2016
Q4 		$23K Buy
1,210
+950
+365% +$169K ﹤0.01% 3336
2016
Q3 		$5K Sell
260
-460
-64% -$79.2K ﹤0.01% 5018
2016
Q2 		$6K Sell
720
-430
-37% -$47.9K ﹤0.01% 4803
2016
Q1 		$68K Sell
1,150
-2,550
-69% -$278K ﹤0.01% 2002
2015
Q4 		$66K Buy
+3,700
New +$662K ﹤0.01% 2179

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cutler Group's BLCM Position: Q3 2020 in Review

Cutler Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2020, closing a stake of 155 shares — an estimated $1K sold.

Cutler Group first reported a position in BLCM in Q4 2015 and held it in 19 quarters. The position peaked at $373K in Q4 2015. 22 funds tracked by Wall St. Rank hold BLCM as of Q3 2020.

  • Cutler Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Cutler Group sold 155 Bellicum Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1K.
  • Cutler Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 19 quarters.
  • Cutler Group's Bellicum Pharmaceuticals, Inc. position peaked at $373K in Q4 2015.
  • 22 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2020.

Based on Cutler Group's 13F filing for Q3 2020, filed 27 Oct 2020.